Total planned funding: $607,340,275
Clear active filters
Johns Hopkins University
University
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
Allocations
Countries/Regions
Mozambique | $142,224,943 |
Tanzania | $95,381,560 |
Kenya | $59,676,646 |
Ethiopia | $58,020,644 |
South Africa | $53,638,557 |
Malawi | $44,989,304 |
Zambia | $39,056,379 |
Côte d'Ivoire | $21,787,907 |
Uganda | $17,421,001 |
Haiti | $15,967,865 |
Namibia | $11,760,963 |
Lesotho | $9,979,153 |
Angola | $9,785,803 |
Botswana | $7,413,940 |
South Sudan | $7,223,348 |
Eswatini | $5,187,201 |
Nigeria | $2,760,596 |
Rwanda | $1,112,570 |
Caribbean Region | $1,100,000 |
India | $1,001,895 |
Ghana | $1,000,000 |
Dominican Republic | $525,000 |
Guyana | $325,000 |
Russia | $0 |
Central America Region | $0 |
Vietnam | $0 |
Organizational Types
University | $607,340,275 |
Program Areas
Prevention | $273,073,020 |
Treatment | $84,785,191 |
Care | $80,773,007 |
Testing | $61,166,939 |
Governance and Systems | $44,286,873 |
Management and Operations | $150,000 |
Budget Codes
CIRC: Biomedical Prevention: Voluntary Medical Male Circumcision | $124,157,330 |
HTXS: Treatment: Adult Treatment | $75,823,668 |
HVOP: Sexual Prevention: Other Sexual Prevention | $66,188,615 |
HVCT: Testing: HIV Testing and Counseling | $61,166,939 |
HVAB: Sexual Prevention: Abstinence/Be Faithful | $40,866,207 |
HKID: Care: Orphans and Vulnerable Children | $36,133,828 |
MTCT: Biomedical Prevention: Prevention of Mother to Child Transmission | $34,756,298 |
OHSS: Health Systems Strengthening | $28,478,099 |
HBHC: Care: Adult Care and Support | $24,675,061 |
HVTB: Care: TB/HIV | $13,862,399 |
HVSI: Strategic Information | $12,455,179 |
PDTX: Treatment: Pediatric Treatment | $8,961,523 |
HMIN: Biomedical Prevention: Injection Safety | $6,954,570 |
PDCS: Care: Pediatric Care and Support | $6,101,719 |
HLAB: Laboratory Infrastructure | $3,353,595 |
HMBL: Biomedical Prevention: Blood Safety | $150,000 |
HVMS: Management and Operations | $150,000 |
IDUP: Prevention: Injecting and Non-Injecting Drug Use | $0 |
HTXD: Treatment: ARV Drugs | $0 |